EphB6受体在恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2020.01.016

摘要/Abstract

摘要： 受体酪氨酸激酶(RTKs)是一种主要的膜受体,调控细胞增殖、分化和迁移。解除RTK信号通路的管制会导致许多疾病,如癌症和发育障碍。促红细胞生成素肝细胞受体(Erythropoietin-producing hepatocellular,Eph)家族是酪氨酸激酶受体家族中最大的一个亚族,其与配体Ephrin的相互作用在生长发育和肿瘤发生过程中发挥着重要作用。研究表明,一种缺乏酪氨酸激酶活性的特殊Eph受体EphB6在乳腺癌、结直肠癌等许多恶性肿瘤中表达下降,而大量证据表明EphB6表达的缺失依赖于其启动子DNA的高甲基化,进而促进肿瘤的进展与转移。EphB6是近期研究的热点因子,本文就其目前在恶性肿瘤中研究进展做一综述。

关键词: EphB6, 恶性肿瘤, 低表达, 发生发展, 甲基化

Abstract: Receptor tyrosine kinases(RTKs)are a major membrane receptor that regulates cell proliferation,differentiation and migration.Deregulation of the RTK signaling pathway can lead to many diseases,such as cancer and developmental disorders.The erythropoietin-producing hepatocellular(Eph)family is the largest subfamily of the tyrosine kinase receptor family,and its interaction with the ligand ephrin plays an important role in the development and tumorigenesis.Studies have shown a special Eph receptor lacking tyrosine kinase activity EphB6 is down-regulated in many malignancies such as breast cancer and colorectal cancer,which is a large amount of evidence that the lack of EphB6 expression is dependent on hypermethylation of its promoter DNA,resulting in promoting the progress and metastasis of tumors.EphB6 is a hot factor in recent studies.This article reviews its current research progress in malignant tumors.

Key words: EphB6, Malignant tumor, Low expression, Development and progression, Methylation

中图分类号:

包乐, 唐丽萍. EphB6受体在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 83-87.

BAO Le, TANG Liping. Progress of the EphB6 receptor in malignant tumors[J]. Journal of Practical Oncology, 2020, 34(1): 83-87.

参考文献

1 Truitt L,Freywald T,Decoteau J,et al.The EphB6 receptor cooperates with c-cbl to regulate the behavior of breast cancer cells[J].Cancer Res,2010,70(3):1141-1153.
2 张晓光,药立波.酪氨酸激酶受体Eph亚族的研究进展[J].生物化学与生物物理进展,1999,1(1):13-17.
3 傅明杰,邢雪.Eph受体家族与肿瘤及肿瘤血管的相关性研究进展[J].临床普外科电子杂志,2014,2(2):53-58.
4 何佳雯,陈公琰.Eph受体家族在肺癌中的研究进展及作为肺癌治疗靶点的可能[J].实用肿瘤学杂志,2018,32(2):164-168.
5 Lisabeth EM,Falivelli G,Pasquale EB.Eph receptor signaling and ephrins[J].CSH Perspect Biol,2013,5(9):9159.
6 Dravis C,Henkemeyer M.Ephrin-B reverse signaling controls septation events at the embryonic midline through separate tyrosine phosphorylation-independent signaling avenues[J].Developmental Biology,2011,355(1):138-151.
7 Fox BP,Kandpal RP.EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells[J].Oncogene,2009,28(14):1706-1713.
8 Fox BP,Kandpal RP.Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR[J].Biochem Bioph Res Co,2006,340(1):268-276.
9 Kandpal RP.DNA-based assay for EphB6 expression in breast carcinoma cells as a potential diagnostic test for detecting tumor cells in circulation[J].Cancer Genomics Proteomics,2010,7(1):9-16.
10 Toosi BM,Zawily AE,Truitt L,et al.EphB6 augments both development and drug sensitivity of triple-negative breast cancer tumours[J].Oncogene,2018,37(30):4073-4093.
11 Hafner C,Bataille F,Meyer S,et al.Loss of EphB6 expression in metastatic melanoma[J].Int J Oncol,2003,23(6):1553-1559.
12 Bailey CM,Kulesa PM.Dynamic interactions between cancer cells and the embryonic microenvironment regulate cell invasion and reveal EphB6 as a metastasis suppressor[J].Mol Cancer Res,2014,12(9):1303-1313.
13 潘笑露,王建东,时姗姗,等.结直肠癌EphB6蛋白的表达及其意义[J].临床肿瘤学杂志,2012,17(3):198-201.
14 陈昌浩,孙岳军,王建东.受体酪氨酸激酶EphB6蛋白在结直肠癌中表达及临床意义[J].东南国防医药,2016,18(4):346-348.
15 Peng L,Tu P,Wang X,et al.Loss of EphB6 protein expression in human colorectal cancer correlates with poor prognosis[J].J Mol Histol,2014,45(5):555-563.
16 Mateo-Lozano S,Bazzocco S,Rodrigues P,et al.Loss of the EPH receptor B6 contributes to colorectal cancer metastasis[J].Scientific Reports,2017,7:43702.
17 彭李博.EphB6在结直肠癌中的表达及其临床病理意义的研究[D].广州:南方医科大学,2014.
18 Bulk E,Yu J,Hascher A,et al.Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer[J].PLoS One,2012,7(12):e44591.
19 铁茹,胡浩,谷仲平,等.EphB6受体型酪氨酸蛋白激酶抑制非小细胞肺癌转移的实验研究[J].陕西医学杂志,2011,40(6):650-652.
20 铁茹,胡浩,谷仲平,等.EphB6受体型酪氨酸蛋白激酶在非小细胞肺癌中高甲基化失活[J].山西医科大学学报,2011,42(3):194-198.
21 Yu J,Bulk E,Ji P,et al.The EphB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer[J].Clin Cancer Res,2010,16(8):2275-2283.
22 丁洁,张荣,余敏敏,等.受体酪氨酸激酶EphB6在卵巢浆液性癌中的表达及其意义[J].临床肿瘤学杂志,2016,21(7):617-620.
23 Gu Y,Li F,Qian N,et al.Expression of EphB6 in ovarian serous carcinoma is associated with grade,TNM stage and survival[J].J Clin Pathol,2016,69(5):448-453.
24 Liu J,Xu B,Xu G,et al.Reduced EphB6 protein in gastric carcinoma and associated lymph nodes suggests EphB6 as a gastric tumor and metastasis inhibitor[J].Cancer Biomarkers,2017,19(3):241-248.
25 陈昌浩,孙岳军.受体酪氨酸激酶EphB6在胃癌中的表达及其临床意义[J].临床肿瘤学杂志,2017,22(12):1111-1115.
26 Mohamed E,Noguchi M,Hamed A,et al.Reduced expression of erythropoietin-producing hepatocyte B6 receptor tyrosine kinase in prostate cancer[J].Oncol Lett,2015,9(4):1672-1676.
27 Fox BP,Tabone CJ,Kandpal RP.Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines[J].Biochem Bioph Res Co,2006,342(4):1263-1272.

[1]	张谊微, 石晶, 刘宇鹏, 曹丽明, 胡付兰, 赵亚双. 外周血USP1基因甲基化与大肠癌预后风险的关系[J]. 实用肿瘤学杂志, 2019, 33(5): 420-424.
[2]	李亚飞, 张霄, 王雪飞, 翁明娇, 王天真. RNA结合蛋白Lin28在恶性肿瘤发生发展中的作用和分子机制[J]. 实用肿瘤学杂志, 2019, 33(5): 456-460.
[3]	普睿, 朱琳, 夏婷婷, 毕皓然, 孙鸿儒, 黄浩, 张磊, 赵亚双. 外周血STAT1,STAT3基因启动子CpG岛甲基化状态与大肠癌预后关系的研究[J]. 实用肿瘤学杂志, 2019, 33(4): 346-351.
[4]	张玫茵娄阁. N6-甲基腺嘌呤与癌症的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 357-360.
[5]	陈宏博, 余增荣, 丁小凡肖林. 盆腔肿瘤IMRT下骨髓剂量-体积参数与急性血液学毒性相关性研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 361-366.
[6]	赵金璐, 李国东刘明. 长链非编码RNA CCAT1与消化系统恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 367-370.
[7]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[8]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[9]	白玉贤, 马仲娟, 苏颖玲, 慕安国, 谢蕊. 胃癌患者FHIT、hMLH1、p16、RAR-beta、Reprimo和TIMP3基因的甲基化研究[J]. 实用肿瘤学杂志, 2019, 33(1): 8-13.
[10]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[11]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.
[12]	韩帮岭, 汪亦民, 薛英威. 中性粒细胞与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 349-352.
[13]	周洁, 陈钰(综述), 陈道桢(审校). 纳米材料在肿瘤光动力治疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 245-249.
[14]	侯思宇(综述), 陈秀玮(审校). JMJD2B蛋白结构功能及在恶性肿瘤发生发展中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 250-253.
[15]	张婷, 侯光营, 王鑫(综述), 贺岩(审校). QKI蛋白在恶性肿瘤中的研究进展及临床意义[J]. 实用肿瘤学杂志, 2018, 32(3): 263-266.